Intellia Therapeutics (NTLA) 3 Aug 232023 Q2 Earnings call transcript

Good morning and welcome to the Intellia Therapeutics' Second Quarter 2023 Earnings Conference Call. My name is Drew and I will be your conference operator today.

Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the Company's request and will be available on the Company's website following the end of the call.

As a reminder, all participants are currently in a listen-only mode. Instructions]. [Operator turn Investor to at Relations now Vice Karp, Intellia. conference of President and the will Ian over Senior I Corporate Communications Please proceed.

a Therapeutics well a press and Welcome outlining the call. Thank morning, this release for this second found quarter, at discussion progress on Intellia as today's broadcast replay Earlier Intellia's & issued website intelliatx.com. Media operator earnings the call Investors be Company's topics quarter live call. This Intellia you, morning, Company's will and on release on archived section the can XXXX being This as good to be is website. everyone. of

At required this that to our call, to this Intellia minute time, management SEC may filings you a refer available forward-looking I ask like sec.gov duty take make discussion listeners a and during presented to Intellia this remind call uncertainties. that potential certain today, update would current and to statements undertakes this law. on risks and for at of unless as by is no All information of information

quarter that, update With to over an XXXX Q&A. second progress, turn financial before on the and will of open for our for Intellia Medical David are Chief Executive with provide Dr. now will Chief Chief Officer; your Dr. review results we programs, Glenn Chief Officer. Laura Leonard, the overview Glenn highlights. Officer; John Lebwohl, Goddard, the Financial John John. our R&D clinical from Laura an Intellia’s and will and David Scientific review recent Dr. I'll Officer; business me Sepp-Lorenzino, begin call will call Joining up

of paradigm At and all genome-editing We're progress leading solutions. across programs clinical platform. shifting of are investigational from you editing deepest foundation ATTR priorities. with these and treatments revolution Not continues and for another Ian our goals amyloidosis morning. lead pipeline our with therapies and Thank with clinical for are [ph] for joining and matrix year genome-editing broadest be learning thank potentially the to the of pleased two us XXXX differentiate novel help particularly a important delivery significant toolbox from the these long we programs. E you, Intellia this patients broader will only two advancement success term strategic a our for set

the in Phase we that as Starting to Notably, with were patients early NTLA-XXXX quarter angioedema the of we fully program of development as handful to X year, treatment to for identify the of months, to we feedback. X just portion next regulatory study. hereditary initiate the able Phase now required ongoing the today enroll third a in announced subject all expect of

expected the submission execution, to people amyloidosis. addition with close a recent IND ATTR clinical for IND submitting NTLA-XXXX positive application. will in trials getting manifestation NTLA-XXXX support the vivo This cardiomyopathy In September, and development, planned pivotal next we're our to very of in update second of data exceptional for

by year people disease. X Some indicates who we initiate there end. as many this world as regulatory suffer from expect may the global to feedback, around XXX,XXX Subject estimates the to be Phase

initiating for believe positions progress over a studies deliver both We to all this next. year this on well us and programs, strategic priority core pivotal

retired over and David clinical detail. hand programs Officer, opportunity Chief the our thank recent call our Lebwohl, growth the over one I'll Members June. Jean-François our to to to achievements. Board the vision David in who founding Board lead to review leadership this will like I'd Medical past Formela integral and who in greater have Lastly, take of our Jean’s been from now decade

halt with amyloidosis and vivo with in in single after the to And with Thanks, begin I'll CRISPR ATTR dose. potential a people everyone. John. candidate welcome disease our reverse XXXX, base living

submit to a for consistent on global track ATTR-CM, in for pivotal our study September prior guidance XXXX. application For of with submission, an mid-year IND are a we

the the of and stages the We are initiate feedback. expect to year IND package preparing end, comprehensive by subject study final in to regulatory

For with for preparations hereditary Phase continuing study. X make ATTR-PN, the to a steady are progress we

we of this the arms present plan to study data additional from ahead, year. Looking both later ongoing

Moving in XXXX to development HAE. for

and mean been have with levels, was were Phase latest in The well The dose for and two interest grade U.S. the rate and attack from of dose of or further. been after all program was tolerated enthusiasm a We enthusiasm medium single follow-up. June reduction pleased any Across at data investigators months even observed the the XXXX and one XXXX in this monthly alike, three has both internationally. a through presented fueled the and patients all temptations, has events really up updated nine severity. XXXX duration in follow XX% in adverse X

for in be current XXXX, planned to allocated morning, Earlier announced that Other Phase all now sites including been all identified patients of enrollment X have Phase will plan the X, study. this interest portion of the Based slots ex-U.S. to level for we sites we part X have on needed the high the Phase sites. complete U.S. of study.

our Following supplemental received to requests the the from preclinical FDA data female inclusion of related potential. the provide childbearing clearance IND, patients of to of

through a be Phase X initial with to an enrolling and FDA, the we of will data generated Such to initiation of the After with at our enrolling being submitted soon that program outside the study. in often While mice a design have as data are amendment, come was submission. on in patients finish. U.S. reproductive could agreement we advance rapidly data protocol study in already with supplied discussion of the study required subgroup the additional we and the have already of have sites ex-U.S. proceeded this supplement along to or part IND now registration

confirm patient study potential, the third The that. By X. diverse women announced ex-U.S., a the Further, XXXX, the subject to main a in the of X great position to optimal we just regulatory to we including today for as objective of that to Phase as expect now forward dose to do feedback. early we quarter is move of X enrolling Phase population Phase childbearing are begin

and look are updates forward the our initiating Officer pivotal full will hand the R&D our over Chief now provide steam for XXXX We who updating you to global Scientific progress on call Laura, study. to I'll on ahead our efforts.

Thank you, David.

our clinic. Beyond and programs pipeline are the vivo lead programs advancing of a towards in we ex vivo

submit to IND end. moving of by For we NTLA vivo this XXXX, We're CTA plan reasons. the conduct program year for in number excited a program, to our first clinic activities into insertion wholly owned a enabling to and continue be

deficiency, effective disease. Based for fatal in from our debilitating antitrypsin normalize are First, a and single levels alpha-X there preclinical few a suffering frequently therapeutic for following options we on believe work, patients can dose. patients alpha-X NTLA-XXXX

across overview Officer more you provide on the gene And a where platform through program to successful, believe high who the need. missing first clinic. our second we progress Intellia’s protein be will updating of move we unmet second NTLA-XXXX Chief diseases enter apply year. Glenn, the financial functional of look as an results. this we will our quarter can of XXXX caused I'll host If a insertion the there to by our our modular Financial Additionally, We half approach broadly to call over R&D to is forward hand

allows morning pipeline sheet and to us Thank you, on to maintain platform. Good Laura. execute continues a Intellia everyone. our strong that balance

and $X interest in of of decrease at the stock XX, income, of plans, million. and $XX.X decrease million by compared driven part billion $X.X equivalents, equity billion December from cash cash, marketable cash of securities company's were $X.X XX, $X.X reimbursements, June XXXX was to net was program. of as by to million offset proceeds million fund The $XXX.X XXXX. Our the proceeds $X.X operations as market of million The in employee based from use approximately collaborator

revenue $XX quarter quarter XXXX million during by to $XX.X decreased XXXX. of collaboration the second million million Our to during $X.X compared of second the

million million of during was programs. R&D the Stock personnel of second XXXX. based during quarter the increase programs quarter by $XX.X $X.X to was XXXX. driven The expenses second the compared of This an G&A $XX.X $X.X in the to of XXXX. to $XX.X quarter the by of growth second mainly million increase million. lead increase expenses compensation related to during based expenses to to Stock second $XXX.X primarily in million of G&A XXXX during of second included million increased the was by and $XX.X for compared expenses quarter XXXX these our support compensation million in the of included $XX second XXXX. based stock was $XX.X compensation for million quarter advancement million R&D quarter increased

half next expect of beyond we XX balance our year. plans operating to the productive a months. fund our very Finally, first the It's certainly been cash

ahead. months number a call the may come questions. still for now will additional With open we you milestones the of the now your for call have that in Q&A. Operator, to open We

[Operator Instructions].

from Jefferies. with The Please Maury ahead. first Raycroft comes go question

Hi, progress after my good clarify morning. in you if will the confidence that case compared When IND and the do trial Congrats have on thanks to size smaller can details and for cleared results disclose HELIOS-B? the based run you base the will you to similar filing September, is recently get be trial you pivotal more XXXX Alnylam’s or the question. IND of taking and design you the study on duration HELIOS-B can trial a

to morning the listeners. Thanks you Maury the question, good for all and

finality past, we with get particulars here. or for and to protocols, respect the is David As Jonas we've when the in to expect some or the the or whether us. in Bridge us With we share do done could not study, focus maybe would you [ph] Bio details more of approach tell less the a to state the same the we of

Yeah, thanks.

about low to people Bridge this details to of we'll likely have levels their us [indiscernible], as a get imagine clearly Bio that to their is we to patients. they hard And good know were the not results. healthy, compound the too details coming think be We'll very very in similar are about mechanism Those to true status that to what and The patient's overall to that be will bit know status, by able very to obviously which there's do We what the the the it first been of a helpful trial. it's in reducing result, they see design Bridge encouraging us as of see do that improve. are more have drug of rates, not we going our that more itself, Bio event these So different up. TTR. and from very after works were was concerned is we TTR, a area obviously resolve need

information it'll think similar be But do chemists, studies about we size to Alnylam well we trial size to to So from HELIOS. trial. are as all later as the use pretty this so coming the that the

ahead. go Please Capital. RBC with Issi Luca from comes question next The

Hi, on Reena this taking question. thanks for for is Luca, my

Just editing last some outside recall, for ask, the so you latest thinking update showed could remind you on tantalizing wanted is I us of year if if in think data vivo I what to there? any liver, us gene-editing hematopoietic wondering had CDXX stem cells, the you

on I outside can you very, that very tell liver. to work continue we Generally vivo the in speaking, editing hard moving

right, to cells data, LMP really approach thinking a use we've things disease, typically transplant, presented road, down editing the an the respect like where stem some encouraging actually hematopoietic a marrow to approach vivo bone to transplant. the with that not to etc. of in You're accompanies would particularly be morbidity do sickle terms preferred avoid cell but in

scientifically, of that will share that variety we think continue come. is that. past body has of beyond work modalities We been there's in assured a are have that different for more ready pursuing the target us that we do say to typical that a to presented we as and we even will I be rest But HSCs work. to

from go The TD Joseph Thome Please next question ahead. with Cowen. comes

one for data this Good think programs, male IND thank in age. guess, TTR-CM disorder was is patients, more spurred any predominantly then additional asked you taking the obviously as childbearing a for and for there is just by and for question. there. the women Hi Maybe this that about older applicability anything upcoming other And I your Thank the my you. FDA, implications guess, morning. the submission? there on to you I and

work data. of careful extensive specifically. they're looked includes There's in We no unaffected. request IND the studies that know cells large we breeding which safety that's data and supplied of provoked this at We've analysis particular germline that very that

itself, the the what the Our the space is from view supplied usually well study as later that so typical the out completing is all. view it to looking our something is us to commonly on way very has supplying in that is But of of for of that we the standpoint work taking the a set appeared said. is to data FDA this speaks considered that a program. fill and done. little have on No we're this we get at and to clinical with etc., study, data, And can this the is FDA

forget At at XXXX. sorry, it's asked you about your patients that implications of and look men that to bias don't point, the see older, this respect I we guess general. before disease, demography I are typically that you of I'm to of a with point set in certainly

fundamental it we program. so way see playing really And with respect the just in to don't out any

Okay, thank you.

And go Greg ahead. Please the of from America. next Harrison comes question Bank with

HAE programs, much looking for programs ongoing? program. other questions. from patients ATTR on this taking morning, great our what received you your hear from is guess, feedback physicians I and the to good Hey, Mary Kate in interest Greg. It's you have at Thank for the so

Maybe at interactions your that are are extensive what learning. this pretty can you speak point, you becoming to David,

ATTR seen patients most all And other an cardiomyopathy. know of treats The we at joining is Yeah, as from the up And And investigator of of and sites we've sites with would do is briskly. of in of with a those studies, lot really enroll centers population end you've that those of studies say group quite or course, who these do leading every there the patients excitement. the study. talked maybe investigators there thanks. hear I were disease. this is the increasing touch with around biggest some amyloidosis with will We world. in who

trying also about if hear need of studies. through is get to that patients of to physician’s want And that We excitement hear some satisfy people into are possible. we course, actually from we these starting there, patients, directly to

estimated the you quickly and know, end to at as be study this get opened to working X as So, year. to as we're of the Phase possible

The Securities. go Please Truist next ahead. question comes with from Joon Lee

thanks is And for good on Hi, [ph] question. Joon. for morning. Mavey This taking our

ZAAT. this still earlier in study X achieved of And on reduction So But patients. Takeda very year, Phase doing [indiscernible] with the is study X improvements XXX fibrosis impact Phase unclear. high XX% liver

NTLA So and for XXXX? your please on could plans elaborate expectations you Thanks.

data David, on other thinking is any thoughts terms XXXX? our affecting of how for

it's We've protein it's very the the Phase and -- for data been study, we're from reducing it's studies. that not a seeing do encouraged of obviously a by the X, the the Takeda of coming benefit we mutant definitive benefit but And think the supportive liver.

this program are into So when And about talking we be for getting clinic. will that completing our IND we'll the that studies year. enabling soon be

Thanks.

comes with Please question next Barclays. The go ahead. from Gena Wang

morning. our on Harshita you is for taking for This Gena, good Hi, questions. thank

quick a clarification. Just

the all prepared this be Phase confirm, I XXXX Phase wanted clarify right you're and why in ex-U.S. be in patients to is not to patients U.S. in think covered for the patients, will study you've enrolled the in right enroll to you X reason identified U.S. X in all X Phase and you've will what's you but you. waiting again, X till waiting remarks for now? that patients of Phase Thank and enroll can the and the this this just

of at are patients you, and into that can mean, Thank identified has said. of in come this quickly some fully is moving the we you're we as the study enrolled. extremely just then and patients as the patients March I the year all you enrolling The identified the here correct, August, began study We've trial. of beginning see. been we've to we've very all and

the that with the the and to investigators those U.S. and needed So enthusiasm to about aggressively for things choice U.S. study contact that to IND reason childbearing the excited capture have is country demographics, and potential feedback work with complete from of program childbearing who of would the U.S., that what that the objective FDA particular that given was site, we're potential have every after clearance to every moved we're the The us. reflected substantially. the same Remember, with very, by accomplishing range means, of doing, which is that, dose way, different into to disease patients that would outside women we're men, etc., we the in ages, of of this And allow women the of identifying successful the of enrolling not, the delayed in do and that's childbearing is the the especially one women potential were states, primary X. Phase goal very we take range and of of we

Phase to in So fast than the wanted to way, U.S. many the weren't work, have By bring given sites come participate rather patients online the FDA, they U.S. enough the that of delay, and to the again, study who to able there X. was anyway. enrollment, idea are complete repeatidity the and submit into the

going we be well to situated So think we're U.S. very in the

abundance an of next to Phase that's potentially program, towards. And the we'll think quarter what the as of I X be have year. we're will early third We well U.S. as begin and prepared patients working

Debjit comes go ahead. question from Partners. Guggenheim next The Please Chattopadhyay with

good Hey, and for the taking question. thanks morning

the Let's advantage respect as you a TTR think to remind you with translate under do could next stand Thanks. Do us where X mid-XX% have for manufacturing, you TTR, you two will you very XXXX. the control Phase over knockdown XX prep tight survival and into that months? studies that over

the The will see patients into point I'll deep work as very very about Well, about, But material that's you and advantage be program. that carries meaningful preparing study. a trials the all address that these we Phase to variance with going X for Phase low a far, across very, commercial convinced reductions to that David that respect is of one critically excited we we're important as having quite pointed for patients. a out have so readiness, X why really your out that observation. readiness the IND we're Phase for put enable lot treated And X

to is achieve looking idea approval that the complete for part this levels it. material the shooting to much for, to you we've is something marketplace. a this benefit. of with how of thinking study, we about in been quickly TTR the always speak so the So if when position add be as in David, to been move that and and have the we're the we've clinical trial, have product how very as a possible the results get duck And respect final ahead to to forward translates that into and

believe these being are do consistency XX% that and can greater agents, who the range, We when means of that the aren't reduction. -- having amounts, with we're patients. deep less potential at than an benefit lesser not XX% only have patients we reductions you we the have getting all There average patients the half great of have but XX% also having other

So important. that's very

The mortality. forward large positive period looking up, these see how on failed important in to fact, in most study. think, need long seen follow cardiovascular we're other terms the is agents. thing that in events we on don't do endpoints out by great our we've we're having you is a That's And to about we of that study Phase of longer in a advantage, X I And think come is study. think include What We've the and their seeing a test. what what will learning study six-minute talked will we're do lot that survival a Bio walk we the benefit Bridge with test. the

ahead. Securities. Zhu question Wells The from Yanan go comes Fargo next Please with

[ph] female think you free certain the questions. for and data U.S. the plan the Thanks age and of do be? so, completing in you agreed has upcoming Thanks. study, that data those data X FDA do would the about upon -- collect from childbearing timeline for patients the points the to the if Phase What might design be supplemental what clinical

quarter. which start abbreviated said it that well in earliest at X With just look and program us, studies I form in to of the not done as be what the study would have earlier, going are that, as all what Well, effect how could three an will proceeds. typical be that respect Phase be month precise are for to advance studies doing in early embryological terms particular it's of that development of we're the

patient So I different well anything think we're women. David, way. that in data our doing on we're collecting for

that They patients the data collection other complete get same get.

effects. look or at any females by We and difference we studies to expect we'll older and any between males or gender patients, younger difference there's all course to other at the if women. Of see things look see don't in

in studies is course, trial on may patients successful know looking have those of are occur to so at getting study. up part move on of a they another We pregnancies specifically Of that who number have after these follow pregnancies. that we the can the

forward Of bringing great can. course, the forward result we future, if in look we to that

And to preclinical any any just reminder the here there's germline involvement in the there's zero been work, audience a in way. that evidence that

life there about is all span. normal important point to needed that other talk not is before, [indiscernible] One for the at gene

So development. that or or -- development fetal

that So humans gene essential know development. not very for well is from we embryo this

it, very you. Thank helpful. Got

next from Dae Ha Please go The ahead. comes with Stifel. Gon question

Hey, Thanks question. good morning, the taking for guys.

from provided was staying animals, this Just peers NHPs of pretty it I as data well I area in also one Boston guess substantial believe preclinical your a as the mice. with idea,

of robust a set still pretty clinical hold. line, demonstrating but germ at data got Looking the

so before they that the much. So size think or related see clearly it sample substantially has any expressed of answered? X substantial any the get from terms their the that Phase have want N questions additional to of confirm be breadth kind that, they many that outlined to you is Thanks can might exactly of kind in FDA and will provide you sufficient, that of how color they experiment size this

of supplied distinction etc. the has that cleared studies in reported is. was question not with That information Yeah, That draw seen what a IND. I this I've breeding is addressed litters, would terms already been between and what with

that the typically with at agents. typically FDA agency, study does development been and I regulatory dealings distinction have has in think, we to been of done is of rest different to is LNP. very that study, particular which modified an question, with supplied. the readily considered way can the the many is we it a the have The do case having said, to any in particular said way view. has abbreviated a I done or as earlier exposed is We which this agreement as something It's, a would sorry, on be germline we're taking that that outset, This as I'm even with addressed, embryological the affected So that that as in call asks little than we the be mice potentially this is, every completing. in quite case, something part This an with which a tell, been is data just put other question our well FDA are far by study. fetus chemicals our and

that look standard with and sharing we to So, forward the stuff information FDA.

Great, thanks much. so

Blair. with go Minter The ahead. next Myles question comes from William Please

thanks Hi, for taking question. our

Just do platform several preclinical you programs? your the another should and the the of once to using on reproductive product Since believe a just does need for different or this platform is per between similar cover just studies. be of generated programs, several study approach one particular sort that guide,

we the goes. studies, material be extensively, will generally we FDA breeding characterized other point the it's that what We've we've for determines speak can't where guide. and done the the any I would applicable expect you different out, require. It as said, is itself no with LNP well, ultimately to results the as that Well,

senses, respects, think about remains the we be way seen. see So immediately as and ultimately that it I think platform many this be should well. FDA answer, will do or to in not how our it may But a that's they whether

next The with question Brian comes Please ahead. J.P. go from Cheng Morgan.

study you? for for Hi, What's are timeline be Yoon, do polyneuropathy? you gating the the granularity on of think you Brian to the Cheng. ATTR And for will more you polyneuropathy factors working questions. with any, in I'm able this if latest a and when bit pivotal what thank give taking some our Sung Thank

David, you want that. to address

been a talking saying of about years. This said We'll we've that preparing pivotal that the later have the lot we of more is are what followed we more two obviously design now data studies. Yeah, patients have and be from than this information year. is

that's it at is point, that to where yet. will we're exactly this so when trial start guiding And not

so this the into is and factors, in great CMC both gating We will about of all -- lot polyneuropathy be course, will be next know who is what this cardiomyopathy. going safety of study a terms issues all patients In resolved.

So factors agreement other design. getting the there on regulatory trial gating are few very than

the at primary the we're regulatory thing that's And looking feedback for point. this

Yes.

you. Thank

next The Please question ahead. William comes from Pickering go with Bernstein.

Hi, you the question. for good morning. Thank

investors use an the the about think benefit, you will the show trial to to to end before outcomes you. progresses endpoints you it and outcomes data? other you see very As as of could clinical profile are CM trial quickly, update that even what the share design, on were and sorts And time towards we take the sharing you this thinking of Thank there clinical differentiated point towards endpoints these that might able the year? be of

David.

could say you blinded I anything share a trial, unfortunately, share data recognize, a from pivotal blinded probably during anything because trial think as by we can't arm. What about we you don't the

have drug. the on So are who patients the drug and we'll off who patients are

done, seen story have is. studies data and call recognize mature. a to studies This you've that should can these you very is will that the we while study, consistent results of However, and in the say that go value or to TTR, We But bring quickly. generally data from do deep as as interpretable, when reductions don't soon will other that mechanistic we type Xs changes these forward take as forward we at can. in do of the that we we meaningful, bring Phase going expect we the we have are results on, everything what happen show we've the

will whenever data. bring we as we up we the that for So wait --

Please Bienkowski with question from Cantor The ahead. comes Fitzgerald. next go Rick

we quick if polyneuropathy of any data a what curious in for good see these from Congrats question from be I'm has dose the Hi, of started. that the it your could morning. end noted and the progress. patients? just was of quarter, the update from re-dosing cohort shared patients of expect XXXX these to low And Last arm data on of could potentially the re-dosing me. type

comment want you re-dosing? do David, on to

all decided but that it future we've know I okay, I haven't think have gone as It's will. as Yeah, about can. whether what the No, We'll put mean, talk we at we this been or to dosed -- we update update point. soon patients well. three we next don't into

Got you. Thank it.

question Please Jay from ahead. Oppenheimer. go next The Olson with comes

Hey, all the taking the and an year, XXXX the Can factors the but thanks for an are a the you about to and pursuing IND? Thank not and question. CTA strategy you. IND talk this congrats a on what behind and rationale for filing gating progress timeline

you to want to David, speak that?

Yeah.

are to that in what you had environment. put regulatory compounds at factors seeing several are we've have all As past, is We is we've those look with the the CTA as other we we quality an of think we to sites, And the IND in that we decide are Gating did what And several pieces going the similar for very to. INDs. what best done sites for other we are together. us investigative the choice. at sites. this of case, that in the key in I that high country the look first at go available, look the that's things We getting

picture agreement CMC Of piece need course, designs. and of you pieces on course applications, is then getting the of our a trial which of big

things those all possible are an as later submission IND. So for

you thank very much. Great,

Securities. Tuerkcan Silvan next from go question JMP ahead. Please comes with The

your Hi, a then potential too potential [ph] general SSL that the end can taking for this I will question. good models we year subsequent with at the more coming anything the example, question and applicable you. thanks reimbursement, Thank off and far from programs that learn in CRISPR my is there HCR the those is just morning for have that or U.S. approval up point? to, be of by

on study there's see of converged the for think, that, But final like interesting, a I Well, emerging will and carefully. that this don't I some obviously, are curative. very, potentially to we those carefully. going I watch trends, we be model has course, very very, think really spaces very drugs world that examples

up that whether moves think Our view will that or in value model efficacy But savings be bar confident deliver be we're the with. the the and to system, U.S. we and for substantially come to health the forward of we to possible right it's healthcare ultimately advantages etc. And will pricing I drug for ex-U.S. efficacy best expect whatever basis is have captures the now that the payers that and the that

you. Thank

The Steve James. next comes question from Seedhouse go Raymond Please with ahead.

genotype? are Hi, the V knock-in on questions homozygous with good so knockout and This patients products is for on AATD, Nick both Steve, to couple morning. intended target

to you David, want that. address

the Yeah, that's V. really need where patients is who homozygous the are for

some agents may lot liver getting and disease would become their there live more with gene. and it's address as type disease both in In lung patients be in they the what One that help need, how these in given are patients is order. terms the give to addresses, tend lungs. be feel -- majority other. is issue is either the patients they patients important. going start That's predominant patients in to disease. where we given should big to disease, longer, of could the overall both lot given The disease. Either end some wild that that one who putting say treat liver want lung of before physicians have patients of with can the be agents Many I be of a patients. the the will liver And by The XX% up knockout, a maybe patients flexibility before affecting who the doesn't so and we have the the patients deficiency group guess knock well, liver the in it disease, the includes time subtle substantial thing both certainly patients, of to because are the other can the is and this over main that the a that knockout is

independent independent but developers. them It be might that remember to pursuing for together, we're programs that important brought as be are can these listeners

have that are not you se. to It's separate going all the for each two are that these requirements Yes, program developed be per fully combination drugs. drugs with a

your compared you same inhibition then with induced by And Thank Okay, elastase AATD the type work do preclinical so neutrophil protein XXXX, got protein? from level it. you. MAAT suspect of the to wild

alpha distinguishable we've X. seen What normal primates was able to presented that circulating from reproduce were is in of in non-human essentially non-human primate levels human approach work in levels this

is our about to Laura, be anything patients thinking that you there add to X? to we're So just the do want may suggests we preclinical that well how to able accomplish is in model and target alpha that.

Yeah, no.

is need but So at you protein that you that ensure to the levels, those you are not the what have. have proteins need TBT frame to only

just John accomplish to in described, non-human expectation that's is to And the humans. what translate the As that's going primate. that we

you. Thank it. Got

Goldman ahead. The next Sachs. question Please Salveen from go comes with Richter

this our Salveen. for taking Shanelle question. you Hi, Tron [ph] is Thank for

they discussions And date? Thank -- on some your color they your questions, that program first PN of on updated to and to allowed to the pivotal Any EACI, not study? on patients the in would XXXX on patients updates attacks. they've on So see have further these withdraw subsequent and a with you from about as the mentioned CM attack provide regulatory remained you your have FDA, were couple In experienced they on you. HAE like spoken what could data in NTLA-XXXX. free prophylaxis the

on and more us David, sure we'll I'm on. having remind goes maybe we XXXX you about as data the could be presented time updates

who that of updated the Recall have I able affect data fairly patients no, attack of we biomarker none in withdrawals And should the you Yeah, received patients report. subsequent all it. a mention XXXX. because as to it those didn't had measures. our recall, prophylaxis would recently give so think [indiscernible] that on were withdraw had use did I we one

amount patients is we a and in a number have that X is seeing However, of that minute withdrawal. withdrawal allow of what the we're we Phase did will be after treated

that course stay When of coming So involves about that agreement preliminary as talk regulators Phase well. But the the is we for to we've the is More tuned. September we've had X, our and U.S. also We FDA, extensive questions we're submission will design that the good the the address in outside IND with have. discussions for doing feel get trial regulators data that will discussions. they that had very IND to

as are will get We PN For needing CM bring a this. little as we earlier. medical the more to as did But details you first need, design. we pivotal forward with PN, push more patients larger agreement a much also we on trial

comes question Suisse. with ahead. next Credit The Richard from Law Please go

learning as and guys, include the on studies? U.S. good based And will outside branded your what Can that market so far? for you products HAE discuss morning. think market XXXX in the the Hey about ex-U.S. usage you the reimbursement rates need for opportunity for you to are

the United work The and an bulk of We that do resource to work our X X desire not the market the product have can eye very we very, seen that we inside to the of HAE have great is those do resides be -- We're centralized very systems. that. today well well Phase course product the through these a we've outside and What aware States. does what the it but of because there's can Phase to to that typically sparing only products States. deliver our best show United will

in greatest that want to it extent the So we that to opportunity exists, participate the market extent possible. to

the different Can ex-U.S., to just see U.S. product? markets for curious affect you the reimbursement compare would versus and the how contrast

for approach again, typically that think drugs. again, as rates typically value That's to how will get And be available. approaches But to I on here. most higher. that's through And are has been resource systems. data disproportionately further be address can think and them. is generally potential expect But down those something particular this demonstrated can we market The centrally U.S. to information of the with this market we we what reimbursed speaking and well publicized will trying later see road. that's that to be to that present sparing, reimbursement the different we are we're it case

thanks. Great,

turn closing our back question-and-answer session. remarks. I concludes would the for to any over This like Karp, Ian to conference

your terrific the all And forward for future Intellia thanks we and look for continued questions to our Great, and interest updates. progress.

So great of and a week. have day great a the rest

has ended. conference The

You may you. disconnect Thank your now line.